From Medscape Oncology

Coverage from the

European Society for Medical Oncology (ESMO) 2018 Congress

October 19 - 23, 2018; Munich, Germany

October 19 - 23, 2018 Munich, Germany

ESMO 2018 Chemo-Free Therapy for Head and Neck Cancer a Step Closer Patients with head and neck cancer who express relatively high levels of PD-L1 could eventually be treated with immunotherapy rather than chemotherapy, new trial data suggest.
Medscape Medical News, October 24, 2018
ESMO 2018 New Data on RT in Prostate Cancer Are 'Practice Changing' For men with newly diagnosed metastatic prostate cancer who have low metastatic burden, radiotherapy to the prostate provides significant survival benefits, say the STAMPEDE investigators.
Medscape Medical News, October 22, 2018
ESMO 2018 'Outstanding' Ovarian Cancer PFS With Olaparib Maintenance Patients with newly diagnosed advanced ovarian cancer have a marked increase in progression-free survival with maintenance olaparib after successful first-line chemotherapy, phase 3 study data indicates.
Medscape Medical News, October 21, 2018

Meeting Highlights At A Glance

Top News From ESMO 2018: Slideshow Practice changing data on prostate cancer, new hope in triple negative breast cancer and the potential for chemo-free head and neck cancer therapy featured prominently this year.

Conference News

ESMO 2018 Impressive Responses for Patients With NTRK Fusion Tumors
Medscape Medical News, November 2, 2018
ESMO 2018 Male Breast Cancer: Current Clinical Practice 'Justified'
Medscape Medical News, October 31, 2018
ESMO 2018 Another Analysis of Trastuzumab for Only 9 Weeks: Not an Option
Medscape Medical News, October 30, 2018
ESMO 2018 Cancer of Unknown Primary: Finding Mutations Alters Therapy
Medscape Medical News, October 29, 2018
ESMO 2018 No Harm, and Maybe Benefit, From Waiting for RAS Status in CRC
Medscape Medical News, October 29, 2018
ESMO 2018 No De-escalation of Therapy for HPV+ Throat Cancer
Medscape Medical News, October 26, 2018
ESMO 2018 Chemo-Free Therapy for Head and Neck Cancer a Step Closer
Medscape Medical News, October 24, 2018
ESMO 2018 Immunotherapy Plus Targeted Drug in First-Line Kidney Cancer
Medscape Medical News, October 22, 2018
ESMO 2018 ONJ With Bone-Modifying Agents in Breast Cancer Patients
Medscape Medical News, October 22, 2018
ESMO 2018 New Data on RT in Prostate Cancer Are 'Practice Changing'
Medscape Medical News, October 22, 2018

ESMO 2018 Novel PI3K inhibitor for Breast Cancer: Success at Last?
Medscape Medical News, October 21, 2018
ESMO 2018 'Outstanding' Ovarian Cancer PFS With Olaparib Maintenance
Medscape Medical News, October 21, 2018
ESMO 2018 Palbociclib in Breast Cancer: New Overall Survival Data
Medscape Medical News, October 21, 2018
ESMO 2018 New Hope in Triple Negative Breast Cancer With Immunotherapy
Medscape Medical News, October 20, 2018
ESMO 2018 Details of Study That Led to Radium-223 Restriction in Europe
Medscape Medical News, October 20, 2018
ESMO 2018 Gender Differences in Chemo Side Effects
Medscape Medical News, October 19, 2018
ESMO 2018 Twitter Widely Used Among Breast Cancer Patients
Medscape Medical News, October 12, 2018
ESMO 2018 CAM Popular, but Cancer Patients Unaware of Risks
Medscape Medical News, October 12, 2018
ESMO 2018 'Revolutionary' Data to Be Presented at ESMO 2018
Medscape Medical News, October 11, 2018

Popular News from ESMO 2017

Top News From ESMO 2017: Slideshow Practice-changing research in advanced renal cell carcinoma, adjuvant therapy for melanoma, and non-small cell lung cancer featured prominently at this year's congress.
Medscape Medical News, Sep 25, 2017
Spare Tire' Ups Cancer Risk More Than High BMI, Fat Percent A Danish observatory study followed postmenopausal woman for 12 years and found that central obesity, but not BMI and fat percentage, places women at an increased risk for cancer diagnosis.
Medscape Medical News, Sep 10, 2017
'Buying a Ford but Paying for a Ferrari': Value in Cancer Care There is a fundamental lack of value in cancer care in which the cost of drugs is unrelated to their impact on clinical outcomes, says an expert who calls for changes in how treatments are assessed.
Medscape Medical News, Oct 12, 2017

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Is Cell-Based Immunotherapy Entering the Mainstream?
Stefan Zimmermann, MD; Fiona Thistlethwaite, MB, BChir, PhD; John B. Haanen, MD, PhD
New Technologies Spread Precision Medicine to the Community
Mark G. Kris, MD; Christian Rolfo, MD, PhD, MBA; Pasi A. Jänne, MD, PhD
Precision Immunotherapy 'Still Years Away'
Stefan Zimmermann, MD; Ignacio Melero, MD, PhD; John B. Haanen, MD, PhD
Lung Cancer Advances: A Year Like No Other
Mark G. Kris, MD; Pasi A. Jänne, MD, PhD; Christian Rolfo, MD, PhD, MBA
Kerr, Tannock on the 'Triangle of Mediocrity' Holding Oncology Back
David J. Kerr, CBE, MD, DSc, FRCP, FMedSci; Ian F. Tannock, MD, PhD, DSc
At ESMO, New Data on Managing Long-term Immunotherapy Responders
H. Jack West, MD
Kathy Miller on IMpassion130: New Standard? Not Yet
Kathy D. Miller, MD
ESMO 2018: 'Tremendous Advances' in Breast Cancer Treatment
Hope S. Rugo, MD; Giuseppe Curigliano, MD, PhD; Fatima F. Cardoso, MD
IMpassion130: 'Encouraging First Signal' for Breast Cancer Immunotherapy
Prof Peter Schmid FRCP, PhD
Big Data, Genomics, and Stealthy Immune Avoiding Tumours
Prof Charles Swanton, MD, PhD
Affordability of New Anti-Cancer Drugs 'Becoming Mission Critical'
Prof Richard Sullivan, PhD, MD

Previous Coverage